Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2010 - 2025)

Emergent BioSolutions' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $12.2 million for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $12.2 million in Q4 2025; TTM through Dec 2025 was $12.2 million, a 55.15% decrease from a year earlier, with the FY2025 full-year figure at $12.2 million, down 55.15% from the prior year.
• Asset Writedowns and Impairment declined to $12.2 million in Q4 2025 per EBS's latest filing, from $27.2 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $306.7 million in Q2 2023 and bottomed at $12.2 million in Q4 2025.
• The 3-year median for Asset Writedowns and Impairment is $27.2 million (2024), against an average of $115.4 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 91.13% in 2024; the steepest drop was 91.13% in 2024.
• Year by year, Asset Writedowns and Impairment stood at $306.7 million in 2023, then plunged by 91.13% to $27.2 million in 2024, then sank by 55.15% to $12.2 million in 2025.
• Per Business Quant, the three latest EBS Asset Writedowns and Impairment figures stand at $12.2 million (Q4 2025), $27.2 million (Q2 2024), and $306.7 million (Q2 2023).